For non-cancer individuals, carriers of a BRCA1 or BRCA2 pathogenic variants was recommended to take more intensive screening and preventive strategies for breast, ovarian, prostate and pancreatic cancer (Elezaby et al., 2019; Daly et al., 2021b). This evidence concerns the gene BRCA2 and cancer.